Skip to content
Search

Latest Stories

Stoke Park country club to shut for two years post takeover by Ambani

STOKE PARK COUNTRY CLUB, one of the most recognised clubs in England, has announced its closure for two years from August 2 to carry out restoration work, a report said.

The five-star hotel that was bought by Indian industrialist Mukesh Ambani just over a month ago for £57 million and will reopen in the summer of 2023, The Telegraph said.


Its golf club and estate will shut on October 18.

The announcement has angered many of its 2,500 members, who have struggled to enjoy its facilities of 27-hole championship course, 13 tennis courts, three restaurants, gymnasium, spa and 49 luxurious rooms during the coronavirus pandemic.

Members, who pay more than £4,000 a year in membership fees, fear the club could become Ambani’s private residence, the newspaper said.

"It's all up in the air. There's talk of it being made into a private residence. A lot of the golf clubs in the UK are being bought over by very rich people from abroad – it's strange," said Des Folliard, a former club golf captain who has played there for 23 years.

The closure will hit the Boodles Challenge, an international five-day tennis exhibition held in the week before Wimbledon, the newspaper said.

Stoke Park will also scale down its 160 staff, with those leaving being "properly compensated for their dedicated service", a club spokesman said.

"The new owners of Stoke Park, Reliance Industries Limited, are making a major investment into the estate and are committed to preserving Stoke Park's rich heritage,” he added.

He added that members remained the "beating heart" of Stoke Park and they look forward to welcoming them back to share a "glorious future".

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less